Gary Owens - Mesa Laboratories COO, Vice President
| MLAB Stock | USD 118.35 1.90 1.63% |
President
Mr. Gary M. Owens is President, Chief Executive Officer, Chief Operating Officer, Director of the Company. Mr. Owens joined us in March 2017 as our Chief Operating Officer. From 2006 through March 2017, Mr. Owens held several positions with Danaher Corporationrationration. From 2016 through March 2017, Mr. Owens served as Corporationrationrate VicePresident of Strategic Development for Danaher Corporation and was seconded to Pall Corporationrationration, a wholly owned subsidiary of Danaher Corporation as Commercial Integration Lead. From 2012 to 2016, Mr. Owens served as VicePresident and General Manager of Beckman Coulter Life Sciences, a wholly owned subsidiary of Danaher Corporationrationration. From 2009 to 2012, Mr. Owens was Corporationrationrate VicePresident of Strategic Development for Danaher Corporationrationration. From 2006 to 2009, Mr. Owens served as the Group VicePresident of Business Development for Danaher Industrial. From 1998 to 2006, Mr. Owens served in various product management, sales and business development roles for Canon Incorporated and Trilogy Software. From 1994 to 1998, Mr. Owens was a team leader for Bain Company since 2017.
| Age | 56 |
| Tenure | 7 years |
| Address | 12100 West Sixth Avenue, Lakewood, CO, United States, 80228 |
| Phone | 303 987 8000 |
| Web | https://www.mesalabs.com |
Gary Owens Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gary Owens against Mesa Laboratories stock is an integral part of due diligence when investing in Mesa Laboratories. Gary Owens insider activity provides valuable insight into whether Mesa Laboratories is net buyers or sellers over its current business cycle. Note, Mesa Laboratories insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mesa Laboratories'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gary Owens over three weeks ago Disposition of 2551 shares by Gary Owens of Mesa Laboratories at 111.976 subject to Rule 16b-3 | ||
Gary Owens over a month ago Acquisition by Gary Owens of 11559 shares of Mesa Laboratories subject to Rule 16b-3 | ||
Gary Owens over three months ago Disposition of 1000 shares by Gary Owens of Mesa Laboratories subject to Rule 16b-3 | ||
Gary Owens over six months ago Acquisition by Gary Owens of 9000 shares of Geospace Technologies subject to Rule 16b-3 |
Mesa Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0169 % which means that it generated a profit of $0.0169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8946) %, meaning that it created substantial loss on money invested by shareholders. Mesa Laboratories' management efficiency ratios could be used to measure how well Mesa Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.58. The current year's Return On Capital Employed is expected to grow to -0.64. At present, Mesa Laboratories' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 354.3 M, whereas Non Currrent Assets Other are forecasted to decline to about 823.6 K.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Kimberly Stoll | Badger Meter | 58 | |
| Olumide JD | Fortive Corp | 52 | |
| Dave Coombe | Vontier Corp | N/A | |
| Daniel Weltzien | Badger Meter | 44 | |
| Gregory Gomez | Badger Meter | 56 | |
| George Verras | Sensata Technologies Holding | 51 | |
| Alyson Barclay | ESCO Technologies | 60 | |
| Sunny Sun | Coherent | N/A | |
| Trina Jashinsky | Badger Meter | 56 | |
| Mark Maiberger | Coherent | N/A | |
| David Naemura | Vontier Corp | 50 | |
| Olumide Soroye | Fortive Corp | 52 | |
| Bill Comeau | ESCO Technologies | N/A | |
| Jacob Sayer | Sensata Technologies Holding | N/A | |
| Andy Warner | ESCO Technologies | N/A | |
| Karen Bauer | Badger Meter | 53 | |
| Jonathan Schwarz | Fortive Corp | 52 | |
| Alain Samaha | Vontier Corp | N/A | |
| Peter Underwood | Fortive Corp | 54 | |
| Vineet Nargolwala | Sensata Technologies Holding | 54 | |
| Jeffrey Cote | Sensata Technologies Holding | 53 | |
Management Performance
| Return On Equity | -0.89 | ||||
| Return On Asset | 0.0169 |
Mesa Laboratories Leadership Team
Elected by the shareholders, the Mesa Laboratories' board of directors comprises two types of representatives: Mesa Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mesa. The board's role is to monitor Mesa Laboratories' management team and ensure that shareholders' interests are well served. Mesa Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mesa Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Dansky, Pres Genomics | ||
| Gary Owens, COO, Vice President | ||
| Brian Archbold, Senior Improvement | ||
| John Sakys, CFO, Chief Accounting Officer and Secretary | ||
| Bryan Leo, VP Operations | ||
| Garrett Krushefski, VP Operations | ||
| John CPA, CFO VP |
Mesa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mesa Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.89 | ||||
| Return On Asset | 0.0169 | ||||
| Profit Margin | (1.08) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 841.33 M | ||||
| Shares Outstanding | 5.43 M | ||||
| Shares Owned By Insiders | 5.74 % | ||||
| Shares Owned By Institutions | 91.82 % | ||||
| Number Of Shares Shorted | 122.97 K | ||||
| Price To Earning | 433.94 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Mesa Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesa Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesa Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesa Laboratories Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. If investors know Mesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesa Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.875 | Dividend Share 0.64 | Earnings Share (45.62) | Revenue Per Share 42.3 | Quarterly Revenue Growth 0.088 |
The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesa Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesa Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesa Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.